Efficacy and Safety of Alisporivir Alone or Combined With... | NCT01215643

NCT01215643

ID	Type	Description	Link
2010-020034-26	EudraCT Number

Status Module

Sponsor/Collaborators Module

Oversight Module

No data available

No data is available for this block.

Description Module

Conditions Module

Design Module

Interventional Study Design

Biospecimen

No data available

No data is available for this block.

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
ALV 1000 mg	Experimental	Alisporivir (ALV) 600 mg twice daily (BID) for 1 week, followed by ALV 1000 mg once daily (QD) during Weeks 2 to 24.	Drug: Alisporivir
ALV 600 mg+RBV	Experimental	Alisporivir (ALV) 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with ribavirin (RBV) during Weeks 2 to 24.	Drug: Alisporivir Drug: Ribavirin
ALV 800 mg+RBV	Experimental	Alisporivir (ALV) 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.	Drug: Alisporivir Drug: Ribavirin
ALV 600 mg+PEG	Experimental	Alisporivir (ALV) 600 mg BID with Peginterferon alfa-2a (PEG) for 1 week, followed by ALV 600 mg QD with PEG once weekly during Weeks 2 to 24.	Drug: Alisporivir Drug: Peginterferon alfa-2a
PEG+RBV	Active Comparator	Peginterferon alfa-2a (PEG) and RBV during Weeks 1 to 24.	Drug: Peginterferon alfa-2a Drug: Ribavirin

Name	Type	Description	Arm Group Labels	Other Names
Alisporivir	Drug	ALV 200 mg soft gel capsules administered orally	ALV 1000 mg ALV 600 mg+PEG ALV 600 mg+RBV ALV 800 mg+RBV

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Percentage of Participants With Rapid Viral Response (RVR) After 4 Weeks of Treatment < the Limit of Quantification (RVR4LOQ)	RVR4LOQ was defined as RVR [serum hepatitis C virus (HCV) ribonucleic acid (RNA) < the limit of quantification (LOQ), i.e., < 25 IU/mL], after 4 weeks of treatment.	after 4 weeks of treatment

Secondary Outcomes

Measure	Description	Time Frame
Percentage of Participants With RVR After 4 Weeks of Treatment < the Limit of Detection (RVR4LOD)	RVR4LOD was defined as Rapid Viral Response (RVR) [serum HCV RNA < the limit of detection (LOD), i.e., < 10 IU/mL], after 4 weeks of treatment.	after 4 weeks of treatment
Percentage of Participants With RVR4LOQ and RVR4LOD (Genotype 2)

Eligibility Module

Contacts/Locations Module

Name	Affiliation	Role
Novartis Pharmceuticals	Novartis Pharmaceuticals	Study Director

Facility	Status	City	State	ZIP	Country	Contacts
Scripps Clinic		La Jolla	California	92037	United States
Sharp Rees-Stealy Medical Group, Inc.

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
26118427	Result	Pawlotsky JM, Flisiak R, Sarin SK, Rasenack J, Piratvisuth T, Chuang WL, Peng CY, Foster GR, Shah S, Wedemeyer H, Hezode C, Zhang W, Wong KA, Li B, Avila C, Naoumov NV; VITAL-1 study team. Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection. Hepatology. 2015 Oct;62(4):1013-23. doi: 10.1002/hep.27960. Epub 2015 Aug 10.

IPD Sharing Statement Module

No data available

No data is available for this block.

Results Section

Participant Flow Module

Arm/Group Information

ID	Title	Description
FG000	ALV 1000 mg	Alisporivir (ALV) 600 mg twice daily (BID) for 1 week, followed by ALV 1000 mg once daily (QD) during Weeks 2 to 24.
FG001	ALV 600 mg+RBV	ALV 600 mg BID with ribavirin (RBV) for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.

Baseline Characteristics Module

Outcome Measures Module

Adverse Events Module

More Info Module

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Submission Tracking

No data available

No data is available for this block.

Condition Browse Module

Intervention Browse Module

Masking Info

All randomized participants

Arm/Group Information

ID	Title	Description
BG000	ALV 1000 mg	ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.
BG001	ALV 600 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.
BG002	ALV 800 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.
BG003	ALV 600 mg+PEG	ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.
BG004	PEG+RBV	PEG and RBV during Weeks 1 to 24.
BG005	Total	Total of all reporting groups

Baseline Measures

Title

Description

Population Description

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Denominator Units Selected

Denominators

Classes

Age, Continuous

Mean

Standard Deviation

years

Title

Denominators

Categories

Title	Measurements
	OG00028.4 OG00136.9 OG00241.9 OG003

Secondary

Percentage of Participants With RVR After 4 Weeks of Treatment < the Limit of Detection (RVR4LOD)

RVR4LOD was defined as Rapid Viral Response (RVR) [serum HCV RNA < the limit of detection (LOD), i.e., < 10 IU/mL], after 4 weeks of treatment.

Full Analysis Set

Posted

Number

percentage of participants

after 4 weeks of treatment

ID	Title	Description
OG000	ALV 1000 mg	ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.
OG001	ALV 600 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.
OG002	ALV 800 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.
OG003	ALV 600 mg+PEG	ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.
OG004

Secondary

Percentage of Participants With RVR4LOQ and RVR4LOD (Genotype 2)

Participants in the Full Analysis Set with genotype 2 HCV infection

Posted

Number

percentage of participants

after 4 weeks of treatment

ID	Title	Description
OG000	ALV 1000 mg	ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.
OG001	ALV 600 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.
OG002	ALV 800 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.
OG003	ALV 600 mg+PEG	ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.
OG004	PEG+RBV	PEG and RBV during Weeks 1 to 24.

Secondary

Percentage of Participants With RVR4LOQ and RVR4LOD (Genotype 3)

Participants in the Full Analysis Set with genotype 3 HCV infection

Posted

Number

percentage of participants

after 4 weeks of treatment

ID	Title	Description
OG000	ALV 1000 mg	ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.
OG001	ALV 600 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.
OG002	ALV 800 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.
OG003	ALV 600 mg+PEG	ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.
OG004	PEG+RBV	PEG and RBV during Weeks 1 to 24.

Secondary

Percentage of Participants With Complete Early Viral Response (cEVR) After 12 Weeks of Treatment (cEVR12LOQ and cEVR12LOD)

cEVR12LOQ and cEVR12LOD were defined as cEVR [serum HCV RNA < LOQ and < LOD] after 12 weeks of treatment, respectively.

Full Analysis Set

Posted

Number

percentage of participants

after 12 weeks of treatment

ID	Title	Description
OG000	ALV 1000 mg	ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.
OG001	ALV 600 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.
OG002	ALV 800 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.
OG003	ALV 600 mg+PEG	ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.
OG004

Secondary

Percentage of Participants With cEVR12LOQ and cEVR12LOD (Genotype 2)

Participants in the Full Analysis Set with genotype 2 HCV infection

Posted

Number

percentage of participants

after 12 weeks of treatment

ID	Title	Description
OG000	ALV 1000 mg	ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.
OG001	ALV 600 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.
OG002	ALV 800 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.
OG003	ALV 600 mg+PEG	ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.
OG004	PEG+RBV	PEG and RBV during Weeks 1 to 24.

Secondary

Percentage of Participants With cEVR12LOQ and cEVR12LOD (Genotype 3)

Participants in the Full Analysis Set with genotype 3 HCV infection

Posted

Number

percentage of participants

after 12 weeks of treatment

ID	Title	Description
OG000	ALV 1000 mg	ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.
OG001	ALV 600 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.
OG002	ALV 800 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.
OG003	ALV 600 mg+PEG	ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.
OG004	PEG+RBV	PEG and RBV during Weeks 1 to 24.

Secondary

Percentage of Participants With End of Treatment Response (ETR) Within 24 Weeks (ETR24LOQ and ETR24LOD)

ETR24LOQ and ETR24LOD were defined as ETR [serum HCV RNA < LOQ and < LOD] after 24 weeks of treatment or when prematurely discontinued.

Full Analysis Set

Posted

Number

percentage of participants

at end of treatment, within 24 weeks

ID	Title	Description
OG000	ALV 1000 mg	ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.
OG001	ALV 600 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.
OG002	ALV 800 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.
OG003	ALV 600 mg+PEG	ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.
OG004

Secondary

Percentage of Participants With ETR24LOQ and ETR24LOD (Genotype 2)

Participants in the Full Analysis Set with genotype 2 HCV infection

Posted

Number

percentage of participants

at end of treatment, within 24 weeks

ID	Title	Description
OG000	ALV 1000 mg	ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.
OG001	ALV 600 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.
OG002	ALV 800 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.
OG003	ALV 600 mg+PEG	ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.
OG004	PEG+RBV	PEG and RBV during Weeks 1 to 24.

Secondary

Percentage of Participants With ETR24LOQ and ETR24LOD (Genotype 3)

Participants in the Full Analysis Set with genotype 3 HCV infection

Posted

Number

percentage of participants

at end of treatment, within 24 weeks

ID	Title	Description
OG000	ALV 1000 mg	ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.
OG001	ALV 600 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.
OG002	ALV 800 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.
OG003	ALV 600 mg+PEG	ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.
OG004	PEG+RBV	PEG and RBV during Weeks 1 to 24.

Secondary

Percentage of Participants With RVR Who Achieved Sustained Viral Response (SVR) 12 Weeks After the End of Treatment (SVR12LOQ and SVR12LOD)

SVR12LOQ and SVR12LOD were defined as Sustained Viral Response (SVR) [serum HCV RNA < LOQ and < LOD] 12 weeks after treatment, respectively.

Full Analysis Set

Posted

Number

percentage of participants

12 weeks after the end of treatment

ID	Title	Description
OG000	ALV 1000 mg	ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.
OG001	ALV 600 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.
OG002	ALV 800 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.
OG003	ALV 600 mg+PEG	ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.

Secondary

Percentage of Participants With RVR Who Achieved SVR12LOQ and SVR12LOD (Genotype 2)

Participants in the Full Analysis Set with genotype 2 HCV infection

Posted

Number

percentage of participants

12 weeks after the end of treatment

ID	Title	Description
OG000	ALV 1000 mg	ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.
OG001	ALV 600 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.
OG002	ALV 800 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.
OG003	ALV 600 mg+PEG	ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.
OG004	PEG+RBV	PEG and RBV during Weeks 1 to 24.

Secondary

Percentage of Participants With RVR Who Achieved SVR12LOQ and SVR12LOD (Genotype 3)

Participants in the Full Analysis Set with genotype 3 HCV infection

Posted

Number

percentage of participants

12 weeks after the end of treatment

ID	Title	Description
OG000	ALV 1000 mg	ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.
OG001	ALV 600 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.
OG002	ALV 800 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.
OG003	ALV 600 mg+PEG	ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.
OG004	PEG+RBV	PEG and RBV during Weeks 1 to 24.

Secondary

Percentage of Participants With RVR Who Achieved SVR at 24 Weeks After the End of Treatment (SVR24LOQ and SVR24LOD)

Full Analysis Set

Posted

Number

percentage of participants

24 weeks after the end of treatment

ID	Title	Description
OG000	ALV 1000 mg	ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.
OG001	ALV 600 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.
OG002	ALV 800 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.
OG003	ALV 600 mg+PEG	ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.
OG004	PEG+RBV	PEG and RBV during Weeks 1 to 24.

Secondary

Percentage of Participants With RVR Who Achieved SVR24LOQ and SVR24LOD (Genotype 2)

Participants in the Full Analysis Set with genotype 2 HCV infection

Posted

Number

percentage of participants

24 weeks after the end of treatment

ID	Title	Description
OG000	ALV 1000 mg	ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.
OG001	ALV 600 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.
OG002	ALV 800 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.
OG003	ALV 600 mg+PEG	ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.
OG004	PEG+RBV	PEG and RBV during Weeks 1 to 24.

Secondary

Percentage of Participants With RVR Who Achieved SVR24LOQ and SVR24LOD (Genotype 3)

Participants in the Full Analysis Set with genotype 3 HCV infection

Posted

Number

percentage of participants

24 weeks after the end of treatment

ID	Title	Description
OG000	ALV 1000 mg	ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.
OG001	ALV 600 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.
OG002	ALV 800 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.
OG003	ALV 600 mg+PEG	ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.
OG004	PEG+RBV	PEG and RBV during Weeks 1 to 24.

Secondary

Percentage of Participants With On-treatment Viral Breakthrough

Viral breakthrough was defined as either:

Confirmed increase of HCV RNA ≥1 log10 above nadir (nadir = lowest HCV RNA value during treatment), or
HCV RNA becoming ≥ 100 IU/mL after previously being undetectable (< LOD) during treatment

Full Analysis Set

Posted

Number

percentage of participants

within 24 weeks of treatment

ID	Title	Description
OG000	ALV 1000 mg	ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.
OG001	ALV 600 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.
OG002	ALV 800 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.
OG003	ALV 600 mg+PEG	ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.

Secondary

Percentage of Participants With Viral Relapse

Viral relapse was defined as having reappearance of detectable HCV RNA after previously being undetectable (< LOD) during treatment.

Full Analysis Set

Posted

Number

percentage of participants

within 24 weeks after the end of treatment

ID	Title	Description
OG000	ALV 1000 mg	ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.
OG001	ALV 600 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.
OG002	ALV 800 mg+RBV	ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.
OG003	ALV 600 mg+PEG	ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.
OG004	PEG+RBV

Arm/Groups

ID	Title	Description	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	ALV 1000 mg: On-treatment AEs	Adverse events (AEs) occurring while on treatment in participants receiving ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.	4	82	64	82
EG001	ALV 600 mg+RBV: On-treatment AEs	AEs occurring while on treatment in participants receiving ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.	1	84	69	84
EG002	ALV 800 mg+RBV: On-treatment AEs	AEs occurring while on treatment in participants receiving ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.	9	94	76	94
EG003	ALV 600 mg+PEG: On-treatment AEs	AEs occurring while on treatment in participants receiving ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.	4	39	37	39
EG004	PEG+RBV: On-treatment AEs	AEs occurring while on treatment in participants receiving PEG and RBV during Weeks 1 to 24.	2	37	30	37
EG005	ALV 1000 mg: Post-treatment AEs	AEs occurring after end of treatment in participants receiving ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.	2	82	10	82
EG006	ALV 600 mg+RBV: Post-treatment AEs	AEs occurring after end of treatment in participants receiving ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.	4	84	10	84
EG007	ALV 800 mg+RBV: Post-treatment AEs	AEs occurring after end of treatment in participants receiving ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.	1	94	13	94
EG008	ALV 600 mg+PEG: Post-treatment AEs	AEs occurring after end of treatment in participants receiving ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.	0	39	5	39
EG009	PEG+RBV: Post-treatment AEs	AEs occurring after end of treatment in participants receiving PEG and RBV during Weeks 1 to 24.	0	37	2	37

Serious Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Acute myocardial infarction	Cardiac disorders	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0020 affected94 at risk EG0030 affected39 at risk EG0040 affected37 at risk EG0050 affected82 at risk EG0060 affected84 at risk EG0071 affected94 at risk EG0080 affected39 at risk EG0090 affected37 at risk
Myocardial infarction	Cardiac disorders	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0020 affected94 at risk EG003
Tachycardia	Cardiac disorders	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0021 affected94 at risk EG003
Hyperthyroidism	Endocrine disorders	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0020 affected94 at risk EG003
Retinopathy	Eye disorders	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0020 affected94 at risk EG003
Abdominal pain	Gastrointestinal disorders	MedDRA (15.0)	Systematic Assessment	EG0001 affected82 at risk EG0010 affected84 at risk EG0020 affected94 at risk EG003
Abdominal pain upper	Gastrointestinal disorders	MedDRA (15.0)	Systematic Assessment	EG0001 affected82 at risk EG0010 affected84 at risk EG0020 affected94 at risk EG003
Diarrhoea	Gastrointestinal disorders	MedDRA (15.0)	Systematic Assessment	EG0001 affected82 at risk EG0010 affected84 at risk EG0021 affected94 at risk EG003
Inguinal hernia	Gastrointestinal disorders	MedDRA (15.0)	Systematic Assessment	EG0001 affected82 at risk EG0010 affected84 at risk EG0020 affected94 at risk EG003
Vomiting	Gastrointestinal disorders	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0021 affected94 at risk EG003
Cellulitis	Infections and infestations	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0021 affected94 at risk EG003
Muscle abscess	Infections and infestations	MedDRA (15.0)	Systematic Assessment	EG0001 affected82 at risk EG0010 affected84 at risk EG0020 affected94 at risk EG003
Pneumonia	Infections and infestations	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0020 affected94 at risk EG003
Pyelonephritis	Infections and infestations	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0020 affected94 at risk EG003
Tubo-ovarian abscess	Infections and infestations	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0020 affected94 at risk EG003
Urinary tract infection	Infections and infestations	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0021 affected94 at risk EG003
Alcohol poisoning	Injury, poisoning and procedural complications	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0020 affected94 at risk EG003
Head injury	Injury, poisoning and procedural complications	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0020 affected94 at risk EG003
Maternal exposure during pregnancy	Injury, poisoning and procedural complications	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0021 affected94 at risk EG003
Toxicity to various agents	Injury, poisoning and procedural complications	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0020 affected94 at risk EG003
Dehydration	Metabolism and nutrition disorders	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0021 affected94 at risk EG003
Hypercalcaemia	Metabolism and nutrition disorders	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0020 affected94 at risk EG003
Muscle spasms	Musculoskeletal and connective tissue disorders	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0011 affected84 at risk EG0020 affected94 at risk EG003
Hepatic neoplasm malignant	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0020 affected94 at risk EG003
Anxiety	Psychiatric disorders	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0020 affected94 at risk EG003
Homicidal ideation	Psychiatric disorders	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0020 affected94 at risk EG003
Major depression	Psychiatric disorders	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0020 affected94 at risk EG003
Panic attack	Psychiatric disorders	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0020 affected94 at risk EG003
Suicidal ideation	Psychiatric disorders	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0020 affected94 at risk EG003
Calculus ureteric	Renal and urinary disorders	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0020 affected94 at risk EG003
Renal colic	Renal and urinary disorders	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0021 affected94 at risk EG003
Chronic obstructive pulmonary disease	Respiratory, thoracic and mediastinal disorders	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0021 affected94 at risk EG003
Hyperventilation	Respiratory, thoracic and mediastinal disorders	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0021 affected94 at risk EG003
Hypoxia	Respiratory, thoracic and mediastinal disorders	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0021 affected94 at risk EG003
Erythema nodosum	Skin and subcutaneous tissue disorders	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0021 affected94 at risk EG003
Hypertension	Vascular disorders	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0020 affected94 at risk EG003

Other Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Anaemia	Blood and lymphatic system disorders	MedDRA (15.0)	Systematic Assessment	EG0008 affected82 at risk EG00111 affected84 at risk EG00210 affected94 at risk EG0034 affected39 at risk EG0043 affected37 at risk EG0050 affected82 at risk EG0060 affected84 at risk EG0071 affected94 at risk EG0080 affected39 at risk EG0090 affected37 at risk
Leukopenia	Blood and lymphatic system disorders	MedDRA (15.0)	Systematic Assessment	EG0003 affected82 at risk EG0012 affected84 at risk EG0022 affected94 at risk EG003
Neutropenia	Blood and lymphatic system disorders	MedDRA (15.0)	Systematic Assessment	EG0009 affected82 at risk EG0018 affected84 at risk EG00213 affected94 at risk EG003
Thrombocytopenia	Blood and lymphatic system disorders	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0015 affected84 at risk EG0023 affected94 at risk EG003
Palpitations	Cardiac disorders	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0012 affected84 at risk EG0026 affected94 at risk EG003
Tachycardia	Cardiac disorders	MedDRA (15.0)	Systematic Assessment	EG0002 affected82 at risk EG0012 affected84 at risk EG0024 affected94 at risk EG003
Motion sickness	Ear and labyrinth disorders	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0020 affected94 at risk EG003
Vertigo	Ear and labyrinth disorders	MedDRA (15.0)	Systematic Assessment	EG0001 affected82 at risk EG0011 affected84 at risk EG0021 affected94 at risk EG003
Hyperthyroidism	Endocrine disorders	MedDRA (15.0)	Systematic Assessment	EG0001 affected82 at risk EG0012 affected84 at risk EG0021 affected94 at risk EG003
Hypothyroidism	Endocrine disorders	MedDRA (15.0)	Systematic Assessment	EG0002 affected82 at risk EG0011 affected84 at risk EG0023 affected94 at risk EG003
Abnormal sensation in eye	Eye disorders	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0020 affected94 at risk EG003
Abdominal distension	Gastrointestinal disorders	MedDRA (15.0)	Systematic Assessment	EG0003 affected82 at risk EG0015 affected84 at risk EG0026 affected94 at risk EG003
Abdominal pain	Gastrointestinal disorders	MedDRA (15.0)	Systematic Assessment	EG0006 affected82 at risk EG0014 affected84 at risk EG0027 affected94 at risk EG003
Abdominal pain upper	Gastrointestinal disorders	MedDRA (15.0)	Systematic Assessment	EG0006 affected82 at risk EG0016 affected84 at risk EG0027 affected94 at risk EG003
Constipation	Gastrointestinal disorders	MedDRA (15.0)	Systematic Assessment	EG0005 affected82 at risk EG0015 affected84 at risk EG0028 affected94 at risk EG003
Diarrhoea	Gastrointestinal disorders	MedDRA (15.0)	Systematic Assessment	EG00013 affected82 at risk EG0016 affected84 at risk EG00210 affected94 at risk EG003
Dry mouth	Gastrointestinal disorders	MedDRA (15.0)	Systematic Assessment	EG0003 affected82 at risk EG0012 affected84 at risk EG0023 affected94 at risk EG003
Dyspepsia	Gastrointestinal disorders	MedDRA (15.0)	Systematic Assessment	EG0007 affected82 at risk EG0018 affected84 at risk EG0027 affected94 at risk EG003
Gastritis	Gastrointestinal disorders	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0012 affected84 at risk EG0020 affected94 at risk EG003
Mouth ulceration	Gastrointestinal disorders	MedDRA (15.0)	Systematic Assessment	EG0005 affected82 at risk EG0010 affected84 at risk EG0023 affected94 at risk EG003
Nausea	Gastrointestinal disorders	MedDRA (15.0)	Systematic Assessment	EG00017 affected82 at risk EG00115 affected84 at risk EG00223 affected94 at risk EG003
Vomiting	Gastrointestinal disorders	MedDRA (15.0)	Systematic Assessment	EG0007 affected82 at risk EG0017 affected84 at risk EG0027 affected94 at risk EG003
Asthenia	General disorders	MedDRA (15.0)	Systematic Assessment	EG00010 affected82 at risk EG0017 affected84 at risk EG00211 affected94 at risk EG003
Chills	General disorders	MedDRA (15.0)	Systematic Assessment	EG0005 affected82 at risk EG0013 affected84 at risk EG0025 affected94 at risk EG003
Fatigue	General disorders	MedDRA (15.0)	Systematic Assessment	EG00021 affected82 at risk EG00123 affected84 at risk EG00230 affected94 at risk EG003
Feeling cold	General disorders	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0022 affected94 at risk EG003
Influenza like illness	General disorders	MedDRA (15.0)	Systematic Assessment	EG0008 affected82 at risk EG0016 affected84 at risk EG0029 affected94 at risk EG003
Injection site erythema	General disorders	MedDRA (15.0)	Systematic Assessment	EG0002 affected82 at risk EG0010 affected84 at risk EG0020 affected94 at risk EG003
Irritability	General disorders	MedDRA (15.0)	Systematic Assessment	EG0002 affected82 at risk EG0015 affected84 at risk EG0028 affected94 at risk EG003
Malaise	General disorders	MedDRA (15.0)	Systematic Assessment	EG0002 affected82 at risk EG0013 affected84 at risk EG0020 affected94 at risk EG003
Pain	General disorders	MedDRA (15.0)	Systematic Assessment	EG0003 affected82 at risk EG0013 affected84 at risk EG0025 affected94 at risk EG003
Pyrexia	General disorders	MedDRA (15.0)	Systematic Assessment	EG00014 affected82 at risk EG00116 affected84 at risk EG00215 affected94 at risk EG003
Hyperbilirubinaemia	Hepatobiliary disorders	MedDRA (15.0)	Systematic Assessment	EG0003 affected82 at risk EG0012 affected84 at risk EG0025 affected94 at risk EG003
Hypersensitivity	Immune system disorders	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0022 affected94 at risk EG003
Nasopharyngitis	Infections and infestations	MedDRA (15.0)	Systematic Assessment	EG0005 affected82 at risk EG0014 affected84 at risk EG0025 affected94 at risk EG003
Upper respiratory tract infection	Infections and infestations	MedDRA (15.0)	Systematic Assessment	EG0002 affected82 at risk EG0013 affected84 at risk EG0024 affected94 at risk EG003
Urinary tract infection	Infections and infestations	MedDRA (15.0)	Systematic Assessment	EG0005 affected82 at risk EG0011 affected84 at risk EG0021 affected94 at risk EG003
Wound	Injury, poisoning and procedural complications	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0020 affected94 at risk EG003
Gamma-glutamyltransferase increased	Investigations	MedDRA (15.0)	Systematic Assessment	EG0001 affected82 at risk EG0011 affected84 at risk EG0021 affected94 at risk EG003
Neutrophil count decreased	Investigations	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0021 affected94 at risk EG003
Platelet count decreased	Investigations	MedDRA (15.0)	Systematic Assessment	EG0001 affected82 at risk EG0013 affected84 at risk EG0022 affected94 at risk EG003
Weight decreased	Investigations	MedDRA (15.0)	Systematic Assessment	EG0004 affected82 at risk EG0012 affected84 at risk EG0024 affected94 at risk EG003
Decreased appetite	Metabolism and nutrition disorders	MedDRA (15.0)	Systematic Assessment	EG00015 affected82 at risk EG00114 affected84 at risk EG00214 affected94 at risk EG003
Arthralgia	Musculoskeletal and connective tissue disorders	MedDRA (15.0)	Systematic Assessment	EG0009 affected82 at risk EG0012 affected84 at risk EG00215 affected94 at risk EG003
Back pain	Musculoskeletal and connective tissue disorders	MedDRA (15.0)	Systematic Assessment	EG0005 affected82 at risk EG0014 affected84 at risk EG00210 affected94 at risk EG003
Muscle spasms	Musculoskeletal and connective tissue disorders	MedDRA (15.0)	Systematic Assessment	EG0004 affected82 at risk EG0013 affected84 at risk EG0023 affected94 at risk EG003
Musculoskeletal pain	Musculoskeletal and connective tissue disorders	MedDRA (15.0)	Systematic Assessment	EG0005 affected82 at risk EG0013 affected84 at risk EG0020 affected94 at risk EG003
Myalgia	Musculoskeletal and connective tissue disorders	MedDRA (15.0)	Systematic Assessment	EG00010 affected82 at risk EG0017 affected84 at risk EG00213 affected94 at risk EG003
Disturbance in attention	Nervous system disorders	MedDRA (15.0)	Systematic Assessment	EG0003 affected82 at risk EG0011 affected84 at risk EG0024 affected94 at risk EG003
Dizziness	Nervous system disorders	MedDRA (15.0)	Systematic Assessment	EG0006 affected82 at risk EG00111 affected84 at risk EG00216 affected94 at risk EG003
Dysgeusia	Nervous system disorders	MedDRA (15.0)	Systematic Assessment	EG0004 affected82 at risk EG0013 affected84 at risk EG0023 affected94 at risk EG003
Headache	Nervous system disorders	MedDRA (15.0)	Systematic Assessment	EG00019 affected82 at risk EG00118 affected84 at risk EG00227 affected94 at risk EG003
Hypoaesthesia	Nervous system disorders	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0012 affected84 at risk EG0021 affected94 at risk EG003
Memory impairment	Nervous system disorders	MedDRA (15.0)	Systematic Assessment	EG0001 affected82 at risk EG0011 affected84 at risk EG0022 affected94 at risk EG003
Paraesthesia	Nervous system disorders	MedDRA (15.0)	Systematic Assessment	EG0001 affected82 at risk EG0011 affected84 at risk EG0023 affected94 at risk EG003
Somnolence	Nervous system disorders	MedDRA (15.0)	Systematic Assessment	EG0002 affected82 at risk EG0011 affected84 at risk EG0021 affected94 at risk EG003
Syncope	Nervous system disorders	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0010 affected84 at risk EG0020 affected94 at risk EG003
Anxiety	Psychiatric disorders	MedDRA (15.0)	Systematic Assessment	EG0008 affected82 at risk EG0019 affected84 at risk EG0025 affected94 at risk EG003
Depressed mood	Psychiatric disorders	MedDRA (15.0)	Systematic Assessment	EG0002 affected82 at risk EG0012 affected84 at risk EG0023 affected94 at risk EG003
Depression	Psychiatric disorders	MedDRA (15.0)	Systematic Assessment	EG00012 affected82 at risk EG0017 affected84 at risk EG0029 affected94 at risk EG003
Insomnia	Psychiatric disorders	MedDRA (15.0)	Systematic Assessment	EG00011 affected82 at risk EG00112 affected84 at risk EG00214 affected94 at risk EG003
Sleep disorder	Psychiatric disorders	MedDRA (15.0)	Systematic Assessment	EG0002 affected82 at risk EG0014 affected84 at risk EG0023 affected94 at risk EG003
Cough	Respiratory, thoracic and mediastinal disorders	MedDRA (15.0)	Systematic Assessment	EG00011 affected82 at risk EG00113 affected84 at risk EG00212 affected94 at risk EG003
Dyspnoea	Respiratory, thoracic and mediastinal disorders	MedDRA (15.0)	Systematic Assessment	EG0003 affected82 at risk EG0016 affected84 at risk EG0023 affected94 at risk EG003
Dyspnoea exertional	Respiratory, thoracic and mediastinal disorders	MedDRA (15.0)	Systematic Assessment	EG0001 affected82 at risk EG0016 affected84 at risk EG0024 affected94 at risk EG003
Oropharyngeal Pain	Respiratory, thoracic and mediastinal disorders	MedDRA (15.0)	Systematic Assessment	EG0005 affected82 at risk EG0012 affected84 at risk EG0025 affected94 at risk EG003
Productive cough	Respiratory, thoracic and mediastinal disorders	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0011 affected84 at risk EG0021 affected94 at risk EG003
Alopecia	Skin and subcutaneous tissue disorders	MedDRA (15.0)	Systematic Assessment	EG00010 affected82 at risk EG0018 affected84 at risk EG0024 affected94 at risk EG003
Dry skin	Skin and subcutaneous tissue disorders	MedDRA (15.0)	Systematic Assessment	EG0008 affected82 at risk EG0015 affected84 at risk EG0026 affected94 at risk EG003
Eczema	Skin and subcutaneous tissue disorders	MedDRA (15.0)	Systematic Assessment	EG0002 affected82 at risk EG0010 affected84 at risk EG0022 affected94 at risk EG003
Erythema	Skin and subcutaneous tissue disorders	MedDRA (15.0)	Systematic Assessment	EG0000 affected82 at risk EG0011 affected84 at risk EG0022 affected94 at risk EG003
Pruritus	Skin and subcutaneous tissue disorders	MedDRA (15.0)	Systematic Assessment	EG00014 affected82 at risk EG00114 affected84 at risk EG00212 affected94 at risk EG003
Rash	Skin and subcutaneous tissue disorders	MedDRA (15.0)	Systematic Assessment	EG00011 affected82 at risk EG0019 affected84 at risk EG00214 affected94 at risk EG003
Hypertension	Vascular disorders	MedDRA (15.0)	Systematic Assessment	EG0009 affected82 at risk EG00110 affected84 at risk EG0028 affected94 at risk EG003

ID	Term
D006526	Hepatitis C
D059350	Chronic Pain

Ancestor Terms

ID	Term
D000086982	Blood-Borne Infections
D003141	Communicable Diseases
D007239	Infections
D006525	Hepatitis, Viral, Human
D014777	Virus Diseases
D018178	Flaviviridae Infections
D012327	RNA Virus Infections
D006505	Hepatitis
D008107	Liver Diseases
D004066	Digestive System Diseases
D010146	Pain
D009461	Neurologic Manifestations
D012816	Signs and Symptoms
D013568	Pathological Conditions, Signs and Symptoms

ID	Term
C499715	alisporivir
C100416	peginterferon alfa-2a
D012254	Ribavirin

EG0040 affected37 at risk

EG0050 affected82 at risk

EG0061 affected84 at risk

EG0070 affected94 at risk

EG0080 affected39 at risk

EG0090 affected37 at risk

EG0040 affected37 at risk

EG0050 affected82 at risk

EG0060 affected84 at risk

EG0070 affected94 at risk

EG0080 affected39 at risk

EG0090 affected37 at risk

EG0040 affected37 at risk

EG0051 affected82 at risk

EG0061 affected84 at risk

EG0070 affected94 at risk

EG0080 affected39 at risk

EG0090 affected37 at risk

EG0040 affected37 at risk

EG0050 affected82 at risk

EG0060 affected84 at risk

EG0070 affected94 at risk

EG0080 affected39 at risk

EG0090 affected37 at risk

EG0040 affected37 at risk

EG0050 affected82 at risk

EG0060 affected84 at risk

EG0070 affected94 at risk

EG0080 affected39 at risk

EG0090 affected37 at risk

EG0040 affected37 at risk

EG0050 affected82 at risk

EG0060 affected84 at risk

EG0070 affected94 at risk

EG0080 affected39 at risk

EG0090 affected37 at risk

EG0040 affected37 at risk

EG0050 affected82 at risk

EG0060 affected84 at risk

EG0070 affected94 at risk

EG0080 affected39 at risk

EG0090 affected37 at risk

EG0040 affected37 at risk

EG0050 affected82 at risk

EG0060 affected84 at risk

EG0070 affected94 at risk

EG0080 affected39 at risk

EG0090 affected37 at risk

EG0040 affected37 at risk

EG0050 affected82 at risk

EG0060 affected84 at risk

EG0070 affected94 at risk

EG0080 affected39 at risk

EG0090 affected37 at risk

EG0040 affected37 at risk

EG0050 affected82 at risk

EG0060 affected84 at risk

EG0070 affected94 at risk

EG0080 affected39 at risk

EG0090 affected37 at risk

EG0040 affected37 at risk

EG0050 affected82 at risk

EG0060 affected84 at risk

EG0070 affected94 at risk

EG0080 affected39 at risk

EG0090 affected37 at risk

EG0040 affected37 at risk

EG0050 affected82 at risk

EG0060 affected84 at risk

EG0070 affected94 at risk

EG0080 affected39 at risk

EG0090 affected37 at risk

EG0041 affected37 at risk

EG0050 affected82 at risk

EG0060 affected84 at risk

EG0070 affected94 at risk

EG0080 affected39 at risk

EG0090 affected37 at risk

EG0040 affected37 at risk

EG0051 affected82 at risk

EG0060 affected84 at risk

EG0070 affected94 at risk

EG0080 affected39 at risk

EG0090 affected37 at risk

EG0040 affected37 at risk

EG0050 affected82 at risk

EG0060 affected84 at risk

EG0070 affected94 at risk

EG0080 affected39 at risk

EG0090 affected37 at risk

EG0040 affected37 at risk

EG0050 affected82 at risk

EG0060 affected84 at risk

EG0070 affected94 at risk

EG0080 affected39 at risk

EG0090 affected37 at risk

EG0040 affected37 at risk

EG0050 affected82 at risk

EG0060 affected84 at risk

EG0070 affected94 at risk

EG0080 affected39 at risk

EG0090 affected37 at risk

EG0040 affected37 at risk

EG0050 affected82 at risk

EG0060 affected84 at risk

EG0070 affected94 at risk

EG0080 affected39 at risk

EG0090 affected37 at risk

EG0041 affected37 at risk

EG0050 affected82 at risk

EG0060 affected84 at risk

EG0070 affected94 at risk

EG0080 affected39 at risk

EG0090 affected37 at risk

EG0040 affected37 at risk

EG0050 affected82 at risk

EG0060 affected84 at risk

EG0070 affected94 at risk

EG0080 affected39 at risk

EG0090 affected37 at risk

EG0040 affected37 at risk

EG0051 affected82 at risk

EG0060 affected84 at risk

EG0070 affected94 at risk

EG0080 affected39 at risk

EG0090 affected37 at risk

EG0040 affected37 at risk

EG0050 affected82 at risk

EG0060 affected84 at risk

EG0070 affected94 at risk

EG0080 affected39 at risk

EG0090 affected37 at risk

EG0040 affected37 at risk

EG0050 affected82 at risk

EG0061 affected84 at risk

EG0070 affected94 at risk

EG0080 affected39 at risk

EG0090 affected37 at risk

EG0040 affected37 at risk

EG0050 affected82 at risk

EG0061 affected84 at risk

EG0070 affected94 at risk

EG0080 affected39 at risk

EG0090 affected37 at risk

EG0040 affected37 at risk

EG0050 affected82 at risk

EG0060 affected84 at risk

EG0070 affected94 at risk

EG0080 affected39 at risk

ID	Term
D012263	Ribonucleosides
D009705	Nucleosides
D009706	Nucleic Acids, Nucleotides, and Nucleosides